MedTrace Logo

A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs

NCT00831129 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2017-02-10

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to examine if a combination of a cholesterol lowering-drug, simvastatin, with a sugar-lowering drug called rosiglitazone is more effective in improving vascular inflammation (irritation of the vessels that transport your blood) and other cardiovascular risk factors than the taking of simvastatin alone.

Conditions

  • Pre-diabetes

Interventions

DRUG

Rosiglitazone

4 mg daily

DRUG

Placebo Rosiglitazone

1 tab daily

DRUG

Simvastatin

40 mg daily

Sponsors & Collaborators

Principal Investigators

  • George Bakris, M.D. · University of Chicago

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2011-03-31
Completion
2011-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00831129 on ClinicalTrials.gov